Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-κB and CHOP expression

被引:12
作者
Pham Thi Thu Huong [1 ,2 ]
Moon, Dong-Oh [1 ]
Kim, Sun Ok [1 ]
Kim, Kyoon Eon [2 ]
Jeong, Sook Jung [1 ]
Lee, Ki Won [3 ]
Lee, Kyung Sang [4 ]
Jang, Jae Hyuk [1 ]
Erikson, Raymond Leo [5 ]
Ahn, Jong Seog [1 ]
Kim, Bo Yeon [1 ]
机构
[1] KRIBB, Chem Biol Res Ctr, Ochangeup 363883, Cheongwongun, South Korea
[2] Chungnam Natl Univ, Coll Nat Sci, Dept Biochem, Taejon 305764, South Korea
[3] Seoul Natl Univ, Ctr Agr Biomat, Dept Agr Biotechnol, Seoul 151921, South Korea
[4] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA
[5] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
基金
新加坡国家研究基金会;
关键词
Proteasome inhibitor-1; Tunicamycin; ER-stress; NF-kappa B; CHOP; ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS; DEATH; THERAPY; PATHWAY; PHOSPHORYLATION; STIMULATION; CASPASE-12; RESISTANCE; ALPHA;
D O I
10.1016/j.cellsig.2011.01.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although endoplasmic reticulum (ER) stress induction by some anticancer drugs can lead to apoptotic death of cancer cells, combination therapy with other chemicals would be much more efficient. It has been reported that proteasome inhibitors could induce cancer cell death through ER-stress. Our study, however, showed a differential mechanism of proteasome inhibitor-I (Pro-I)-induced cell death. Pro-I significantly enhanced apoptotic death of PO prostate cancer cells pretreated with tunicamycin (TM) while other signaling inhibitors against p38. mitogen activated kinase (MEK) and phosphatidyl-inositol 3-kinase (PI3K) did not, as evidenced by cell proliferation and cell cycle analyses. NF-kappa B inhibition by Pro-I, without direct effect on ER-stress, was found to be responsible for the TM-induced chemosensitization of PC3 cells. Moreover, TM-induced/enhancer-binding protein (C/EBP) homologous protein (CHOP) expression was enhanced by Pro-I without change in GRP78 expression. CHOP knockdown by siRNA also showed a significant decrease in Pro-I chemosensitization. All these data suggest that although TM could induce both NF-kappa B activation and CHOP expression through ER-stress, both NF-kappa B inhibition and increased CHOP level by Pro-I are required for enhanced chemosensitization of PC3 prostate cancer cells. Thus. our study might contribute to the identification of anticancer targets against prostate cancer cells. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:857 / 865
页数:9
相关论文
共 29 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] STIMULATION-DEPENDENT I-KAPPA-B-ALPHA PHOSPHORYLATION MARKS THE NF-KAPPA-B INHIBITOR FOR DEGRADATION VIA THE UBIQUITIN-PROTEASOME PATHWAY
    ALKALAY, I
    YARON, A
    HATZUBAI, A
    ORIAN, A
    CIECHANOVER, A
    BEN-NERIAH, Y
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) : 10599 - 10603
  • [3] Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
    Arlt, A
    Gehrz, A
    Müerköster, S
    Vorndamm, J
    Kruse, ML
    Fölsch, UR
    Schäfer, H
    [J]. ONCOGENE, 2003, 22 (21) : 3243 - 3251
  • [4] Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
    Arlt, A
    Vorndamm, J
    Breitenbroich, M
    Fölsch, UR
    Kalthoff, H
    Schmidt, WE
    Schäfer, H
    [J]. ONCOGENE, 2001, 20 (07) : 859 - 868
  • [5] Cytoprotection following endoplasmic reticulum stress protein induction in continuous cell lines
    Bedard, K
    MacDonald, N
    Collins, J
    Cribb, A
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (03) : 124 - 131
  • [6] Considerations in the design and development of transport inhibitors as adjuncts to drug therapy
    Dantzig, AH
    de Alwis, DP
    Burgess, M
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) : 133 - 150
  • [8] Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2
    Häcki, J
    Egger, L
    Monney, L
    Conus, S
    Rossé, T
    Fellay, I
    Borner, C
    [J]. ONCOGENE, 2000, 19 (19) : 2286 - 2295
  • [9] Janssen YMW, 1999, METHOD ENZYMOL, V300, P363
  • [10] Phosphorylation meets ubiquitination:: The control of NF-κB activity
    Karin, M
    Ben-Neriah, Y
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 : 621 - +